HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Thursday, November 12, 2026 at 4:30 p.m. Eastern
Device demonstrated higher specificity than standard 12-lead ECG (81.8% vs. 71.4%), with comparable sensitivity
HeartBeam ECGs were interpreted more consistently across cardiologists than standard 12-lead
ALIGN-ACS pilot study compared the HeartBeam 3D ECG technology to a standard 12-lead ECG for detection of acute coronary syndrome (ACS)
Results will inform the design of HeartBeam’s planned U.S. pivotal study,
Acceptance into FDA’s TAP Pilot follows Breakthrough Device Designation granted earlier this month for HeartBeam’s heart attack assessment technologyTAP Pilot provides dedicated FDA advisors and early engagement with
HEADSTART-ACS study conducted in collaboration with Indonesia’s National Cardiovascular Center in world’s fourth most populous country, representing strategically significant market of 288 million people
Data
HeartBeam joins Philips, Medtronic, GE HealthCare and other global healthcare leaders in the EU-funded EXIT-CVD research consortium
HeartBeam will lead the HEART-CHECK Study, one of the project’s 22
Designation recognizes the potential of HeartBeam’s 3D ECG technology to help physicians assess suspected heart attacks outside the hospitalBreakthrough status provides prioritized FDA interaction as HeartBeam advances
HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today issued a letter to shareholders from its Executive Chairman Richard
Completed Enrollment in ALIGN-ACS Heart Attack Detection Pilot Study Ahead of Schedule; Full Results to be Presented at TCT 2026
Surpassed 50% Enrollment Ahead of Schedule in Indonesian Government-Supported
HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Thursday, August 13, 2026 at 4:30 p.m. Eastern
Patent extends HeartBeam's ECG hardware platform with multi-modal sensing capabilities
Acoustic sensors enable HeartBeam’s device to function as a "digital stethoscope" to assess heart valve
Accelerated enrollment completion in ALIGN-ACS study underscores HeartBeam’s execution on its key strategic priority of heart attack detectionData analysis is underway, with full results anticipated for presentation at
Company will license its 3D ECG signal technology to established partners, moving beyond direct medical device sales
Advancing toward heart attack detection as a key expansion of the platform
Tailoring its
Publication in JACC: Advances demonstrates that an algorithm combining the HeartBeam ECG device with patient risk factors and symptoms can accurately identify heart attack risk
Study advances the scientific
